MESNA-CLARIS mesna 200 mg/2 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

mesna-claris mesna 200 mg/2 ml solution for injection ampoule

baxter healthcare pty ltd - mesna, quantity: 100 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections; nitrogen; sodium hydroxide - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects sections of the cyclophosphamide and ifosfamide product information).

MESNA-CLARIS mesna 400 mg/4 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

mesna-claris mesna 400 mg/4 ml solution for injection ampoule

baxter healthcare pty ltd - mesna, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; nitrogen; water for injections; disodium edetate - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects sections of the cyclophosphamide and ifosfamide product information).

MESNA-CLARIS mesna 1000 mg/10 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

mesna-claris mesna 1000 mg/10 ml solution for injection ampoule

baxter healthcare pty ltd - mesna, quantity: 100 mg/ml - injection, solution - excipient ingredients: water for injections; nitrogen; sodium hydroxide; disodium edetate; benzyl alcohol - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects sections of the cyclophosphamide and ifosfamide product information).

Uromitexan 100mg/ml Solution for Injection or infusion (4ml ampoule) Malta - English - Medicines Authority

uromitexan 100mg/ml solution for injection or infusion (4ml ampoule)

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - mesna - solution for infusion or injection - mesna 100 mg/ml - all other therapeutic products

Uromitexan 100mg/ml Solution for Injection or infusion (10ml ampoule) Malta - English - Medicines Authority

uromitexan 100mg/ml solution for injection or infusion (10ml ampoule)

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - mesna - solution for infusion or injection - mesna 100 mg/ml - all other therapeutic products

Uromitexan New Zealand - English - Medsafe (Medicines Safety Authority)

uromitexan

baxter healthcare ltd - mesna 100 mg/ml;   - solution for injection - 100 mg/ml - active: mesna 100 mg/ml   excipient: disodium edetate dihydrate sodium hydroxide water for injection - for the prophylaxis of haematuria and haemorrhagic cystitis in patients treated with cyclophosphamide or ifosfamide in doses considered to be urotoxic. uromitexan is also indicated in at risk patients even though these patients may be receiving relatively low doses of oxazaphosphorines. at risk patients include those that have experienced previous irradiation of the small pelvis, cystitis with earlier oxazaphosphorine therapy, and/or a case history of urinary tract disease.

MESNA injection, solution United States - English - NLM (National Library of Medicine)

mesna injection, solution

baxter healthcare corporation - mesna (unii: nr7o1405q9) (2-mercaptoethanesulfonic acid - unii:vhd28s0h7f) - mesna 100 mg in 1 ml - mesna is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. limitation of use: mesna is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. mesna is contraindicated in patients known to be hypersensitive to mesna or to any of the excipients [see warnings and precautions (5.1)] . risk summary mesna is used in combination with ifosfamide or other cytotoxic agents. ifosfamide can cause fetal harm when administered to a pregnant woman. refer to the ifosfamide prescribing information for more information on use during pregnancy. mesna injection contains the preservative benzyl alcohol. because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely [see warnings and precautions (5.3) and use in specific populations (8.4)]. the estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. all pregnancies

MESNA- mesna injection solution United States - English - NLM (National Library of Medicine)

mesna- mesna injection solution

gland pharma limited - mesna (unii: nr7o1405q9) (2-mercaptoethanesulfonic acid - unii:vhd28s0h7f) - mesna 100 mg in 1 ml - mesna injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. limitation of use : mesna injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. mesna injection is contraindicated in patients known to be hypersensitive to mesna or to any of the excipients [see warnings and precautions (5.1)]. risk summary mesna injection is used in combination with ifosfamide or other cytotoxic agents. ifosfamide can cause fetal harm when administered to a pregnant woman. refer to the ifosfamide prescribing information for more information on use during pregnancy. mesna injection contains the preservative benzyl alcohol. because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely [see warnings and precautions (5.3) and use in specific populations (8.4)]. the estimated background risk of major birth defects and miscarriage fo

MESNA injection, solution United States - English - NLM (National Library of Medicine)

mesna injection, solution

teva parenteral medicines, inc. - mesna (unii: nr7o1405q9) (2-mercaptoethanesulfonic acid - unii:vhd28s0h7f) - mesna 100 mg in 1 ml - mesna injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. limitation of use: mesna injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. mesna is contraindicated in patients known to be hypersensitive to mesna or to any of the excipients [see warnings and precautions (5.1)]. risk summary mesna is used in combination with ifosfamide or other cytotoxic agents. ifosfamide can cause fetal harm when administered to a pregnant woman. refer to the ifosfamide prescribing information for more information on use during pregnancy. mesna injection contains the preservative benzyl alcohol. because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely [see warnings and precautions (5.3) and use in specific populations (8.4)]. the estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. all